Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Revenue (2016 - 2025)

Historic Revenue for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to $249.3 million.

  • Tandem Diabetes Care's Revenue rose 216.5% to $249.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 1786.74%. This contributed to the annual value of $940.2 million for FY2024, which is 2574.3% up from last year.
  • Latest data reveals that Tandem Diabetes Care reported Revenue of $249.3 million as of Q3 2025, which was up 216.5% from $240.7 million recorded in Q2 2025.
  • Over the past 5 years, Tandem Diabetes Care's Revenue peaked at $282.6 million during Q4 2024, and registered a low of $141.0 million during Q1 2021.
  • In the last 5 years, Tandem Diabetes Care's Revenue had a median value of $200.3 million in 2022 and averaged $206.1 million.
  • Its Revenue has fluctuated over the past 5 years, first soared by 5758.45% in 2021, then crashed by 1075.09% in 2023.
  • Over the past 5 years, Tandem Diabetes Care's Revenue (Quarter) stood at $210.0 million in 2021, then rose by 5.0% to $220.5 million in 2022, then decreased by 10.75% to $196.8 million in 2023, then skyrocketed by 43.62% to $282.6 million in 2024, then fell by 11.82% to $249.3 million in 2025.
  • Its Revenue stands at $249.3 million for Q3 2025, versus $240.7 million for Q2 2025 and $234.4 million for Q1 2025.